Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Oct. 15, 2021
Summary Of Significant Accounting Policies [Line Items]
Common stock and paid-in capital, shares outstanding	53,990,000		53,877,000
Due from Radionetics	$ 99,000		$ 135,000
Radionetics Warrant
Summary Of Significant Accounting Policies [Line Items]
Additional common shares issued				3,407,285
Radionetics [Member]
Summary Of Significant Accounting Policies [Line Items]
Aggregate equity interest	56.00%
Radionetics Oncology, Inc.
Summary Of Significant Accounting Policies [Line Items]
Due from Radionetics	$ 100,000		100,000
Reimbursments earned	$ 13,000		$ 600,000
Dr. Struthers | Radionetics Oncology, Inc.
Summary Of Significant Accounting Policies [Line Items]
Vest ratably months	36 months
Annual retainer receives	$ 50,000
Australian Research and Development Tax Incentive | Australian Taxation Office
Summary Of Significant Accounting Policies [Line Items]
Tax incentive receivable, reductions to research and development expense	$ 21,000	$ 146,000
Restricted common stock | Dr. Struthers | Radionetics Oncology, Inc.
Summary Of Significant Accounting Policies [Line Items]
Common stock and paid-in capital, shares outstanding	1,000,000